Bespoke Extracts (BSPK) Interest & Investment Income (2022 - 2023)
Bespoke Extracts (BSPK) reported Interest & Investment Income of $2587.0 for Q2 2023, up 934.8% on a YoY basis from $250.0 in Q2 2022, and down 5.93% sequentially from $2750.0 in Q1 2023.
Bespoke Extracts (BSPK) Interest & Investment Income (2022 - 2023) Analysis & Trends
Bespoke Extracts (BSPK) has 2 years of Interest & Investment Income data on file, last reported at $2587.0 in Q2 2023.
- For the quarter ending Q2 2023, Interest & Investment Income rose 934.8% year-over-year to $2587.0; the trailing twelve-month figure through Jun 2023 stood at $5837.0 (changed N/A YoY), and the FY2022 full-year result was $931.0, changed N/A from the prior year.
- Interest & Investment Income slipped to $2587.0 in Q2 2023, from $2750.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $2750.0 in Q1 2023 to a low of $53.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 2,587.00 |
| Mar 31, 2023 | 2,750.00 |
| Dec 31, 2022 | 53.00 |
| Sep 30, 2022 | 447.00 |
| Jun 30, 2022 | 250.00 |
| Mar 31, 2022 | 181.00 |